Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cellistic
Mont-Saint-Guilbert, Belgiumcellistic.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Cellistic provides proprietary iPSC-based platforms—Pulse™ for rapid generation of edited iPSC lines and Echo™ for scalable GMP manufacturing of differentiated immune effector cells. The company’s technologies are designed to accelerate timelines from concept through IND-enabling studies. Clinical results pertain to partner programs enabled by these platforms rather than in-house therapeutics.
- Therapeutic areas
- Oncology
- Modalities
- Induced pluripotent stem cell (iPSC)-based cell therapiesAllogeneic cell therapiesImmune cell therapies (NK cells, α/β T cells, γ/δ T cells, macrophages)
- Industry
- Drug Discovery Services
02
Partnerships
Not specifically named, but works with multiple autologous and allogeneic cell therapy developers as contract development/manufacturing partner.
Beyond the preview
Go deeper on Cellistic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellistic.